Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response

Human Reproduction Update

Volumn 21, Issue 6, 2015, Pages 698-710

  Iliodromiti, Stamatina ^a   Anderson, Richard A ^b   Nelson, Scott M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anti M llerian hormone; Antral follicle count; Inter individual variation; Intra individual variation; Ovarian response

Indexed keywords

CORIFOLLITROPIN ALFA; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN; BIOLOGICAL MARKER;

ANTRAL FOLLICLE COUNT; ARTICLE; BODY MASS; COMORBIDITY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE GENITAL TRACT PARAMETERS; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; NONHUMAN; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARIAN RESPONSE; OVARY FUNCTION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREDICTIVE VALUE; PREGNANCY RATE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TRANSVAGINAL ECHOGRAPHY; BLOOD; DRUG EFFECTS; FEMALE; OVARY FOLLICLE; OVULATION INDUCTION; PERSONALIZED MEDICINE; PHYSIOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ANTI-MULLERIAN HORMONE; BIOMARKERS; FEMALE; HUMANS; OVARIAN FOLLICLE; OVULATION INDUCTION; PRECISION MEDICINE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84947599748     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmu062     Document Type: Article

References (131)

1. Almog B, Shehata F, Shalom-Paz E, Tan SL, TulandiT. Age-related normogram for antral follicle count: McGill reference guide. Fertil Steril 2011a;95:663-666.
2. Almog B, Shehata F, Suissa S, Holzer H, Shalom-Paz E, La Marca A, Muttukrishna S, Blazar A, Hackett R, Nelson SM, et al. Age-related normograms of serum antimullerian hormone levels in a population of infertile women: a multicenter study. Fertil Steril 2011b;95:2359-63, 63 e1.
3. Andersen AN, Witjes H, Gordon K, Mannaerts B. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod 2011; 26:3413-3423.
4. Anderson EL, Fraser A, McNally W, Sattar N, Lashen H, Fleming R, Nelson SM, Lawlor DA. Anti-müllerian hormone is not associated with cardiometabolic risk factors in adolescent females. PLoS One 2013;8:e64510.
5. Anderson RA, Themmen AP, Al-Qahtani A, GroomeNP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006;21:2583-2592.
6. Anderson RA, Nelson SM, Wallace WH. Measuring anti-Mullerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas 2012; 71:28-33.
7. Anderson RA, McIlwain L, Coutts S, Kinnell HL, Fowler PA, Childs AJ. Activation of the aryl hydrocarbon receptor by a component of cigarette smoke reduces germ cell proliferation in the human fetal ovary. Mol Hum Reprod 2014;20:42-48.
8. AnshLabs picoAMH ELISA package insert. Available at: http://www.anshlabs.com/wp-content/uploads/inserts/AL124-i.pdf (May 2014, date last accessed).
9. AnshLabs UltraSensitive AMH/MIS ELISA package insert. Available at: http://www.diagnosmed.com/sites/default/files/Ultra%20sensitive%20AMH-Elisa.pdf (May 2014, date last accessed).
10. Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013a;99:1644-1653 e1.
11. Arce JC, la Marca A, Klein BM, NyboeAndersen A, Fleming R.Reply of the authors. Fertil Steril 2013b;100 e10.
12. Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update 2012;18:73-91.
13. Baker ML, Metcalfe SA, Hutson JM. Serum levels of mullerian inhibiting substance in boys from birth to 18 years, as determined by enzyme immunoassay. J Clin Endocrinol Metab 1990;70:11-15.
14. Basama FM, Crosfill F, Price A.Women's perception of transvaginal sonography in the first trimester; in an early pregnancy assessment unit. Arch Gynecol Obstet 2004; 269:117-120.
15. Beckman Coulter AMH Gen II ELISA package insert 2013.
16. Beckman Coulter. Access AMH Instructions for Use, September 2014. REF B13127.
17. Bentzen JG, Forman JL, Pinborg A, Lidegaard Ø, Larsen EC, Friis-Hansen L, Johannsen TH, Nyboe Andersen A. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. Reprod Biomed Online 2012;25:612-619.
18. Bentzen JG, Forman JL, Johannsen TH, Pinborg A, Larsen EC, Andersen AN. Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab 2013;98:1602-1611.
19. Bleil ME, Gregorich SE, Adler NE, Sternfeld B, Rosen MP, Cedars MI. Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women. Fertil Steril 2014; 101:199-207.
20. Broekmans FJ, Faddy MJ, Scheffer G, te Velde ER. Antral follicle counts are related to age at natural fertility loss and age at menopause. Menopause 2004; 11:607-614.
21. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006; 12:685-718.
22. Broekmans FJ, de Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil Steril 2010;94:1044-1051.
23. Broekmans FJ, Verweij PJ, Eijkemans MJ, Mannaerts BM, Witjes H. Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2014;29:1688-1697.
24. Broer SL, Mol BWJ, Hendriks D, Broekmans FJM. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009;91:705-714.
25. Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 2011;17:46-54.
26. Broer SL, Dolleman M, van Disseldorp J, Broeze KA, Opmeer BC, Bossuyt PM, Eijkemans MJ, Mol BW, Broekmans FJ. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril 2013a;100:420-429.e7.
27. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, Eijkemans MJC, Mol BWJ, Broekmans FJM, Anderson RA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013b;19:26-36.
28. Brouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ. Levels of serum anti-Mullerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:1534-1538.
29. Bungum L, Jacobsson AK, Rosen F, Becker C, Andersen CY, Guner N, Giwercman A. Circadian variation in concentration of anti-Mullerian hormone in regularly menstruating females: relation to age, gonadotrophin and sex steroid levels. Hum Reprod 2011;26:678-684.
30. Charleston JS, Hansen KR, Thyer AC, Charleston LB, Gougeon A, Siebert JR, Soules MR, Klein NA. Estimating human ovarian non-growing follicle number: the application of modern stereology techniques to an old problem. Hum Reprod 2007;22:2103-2110.
31. Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998;69: 505-510.
32. Codner E, Iniguez G, Hernandez IM, Lopez P, Rhumie HK, Villarroel C, Rey RA. Elevated anti-Mullerian hormone (AMH) and inhibin B levels in prepubertal girls with type 1 diabetes mellitus. Clin Endocrinol 2011;74:73-78.
33. Cui Y, Shi Y, Cui L, Han T, Gao X, Chen ZJ. Age-specific serum antimüllerian hormone levels in women with and without polycystic ovary syndrome. Fertil Steril 2014; 102:230-236.e2.
34. Deb S, Jayaprakasan K, Campbell BK, Clewes JS, Johnson IR, Raine-Fenning NJ. Intraobserver and interobserver reliability of automated antral follicle counts made using three-dimensional ultrasound and SonoAVC. Ultrasound Obstet Gynecol 2009;33:477-483.
35. Deb S, Campbell BK, Pincott-Allen C, Clewes JS, Cumberpatch G, Raine-Fenning NJ. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound. Ultrasound Obstet Gynecol 2012;39:574-580.
36. Deb S, Campbell BK, Clewes JS, Pincott-Allen C, Raine-Fenning NJ. Intracycle variation in number of antral follicles stratified by size and in endocrine markers of ovarian reserve in women with normal ovulatory menstrual cycles. Ultrasound Obstet Gynecol 2013;41:216-222.
37. Decanter C, Peigne M, Mailliez A, Morschhauser F, Dassonneville A, Dewailly D, Pigny P. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay. Fertil Steril 2014;102:483-487.
38. Dennis N, Denizot P, Lejeune C, Riviere D, Nicouleau L, Bord S, Marquet PY, Beckman Coulter Inc. Assessment of performance of an automated AMH immunoassay. ESHRE Munich 2014.
39. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011;26:3123-3129.
40. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014a;20:370-385.
41. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, Escobar-Morreale HF. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014b;20:334-352.
42. Dolleman M, Verschuren WM, Eijkemans MJ, Dolle ME, Jansen EH, Broekmans FJ, van der Schouw YT. Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study. J Clin Endocrinol Metab 2013;98:2106-2115.
43. Dutta RL, Economides DL. Patient acceptance of transvaginal sonography in the early pregnancy unit setting. Ultrasound Obstet Gynecol 2003;22:503-507.
44. Ebbel E, Katz A, Kao N, Cedars M. Reproductive aged women with cancer have a lower antral follicle count than expected. Fertil Steril 2011;96:S199-S200.
45. Elter K, Sismanoglu A, Durmusoglu F. Intercycle variabilities of basal antral follicle count and ovarian volume in subfertile women and their relationship to reproductive aging: a prospective study. Gynecol Endocrinol 2005;20:137-143.
46. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323-327.
47. Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005;20:923-927.
48. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616-1624.
49. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006;85:592-596.
50. FreemanEW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 2012; 97:1673-1680.
51. Freour T, Masson D, Mirallie S, Jean M, Bach K, Dejoie T, Barriere P. Active smoking compromises IVF outcome and affects ovarian reserve. Reprod Biomed Online 2008;16:96-102.
52. Freour T, Masson D, Dessolle L, Allaoua D, Dejoie T, Mirallie S, Jean M, Barriere P. Ovarian reserve and in vitro fertilization cycles outcome according to women smoking status and stimulation regimen. Arch Gynecol Obstet 2012;285:1177-1182.
53. Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril 2012;97:125-133.
54. Gannon AM, Stampfli MR, Foster WG. Cigarette smoke exposure leads to follicle loss via an alternative ovarian cell death pathway in a mouse model. Toxicol Sci 2012; 125:274-284.
55. Gassner D, Jung R. First fully automated immunoassay for anti-Müllerian hormone. Clin Chem Lab Med 2014;52:1143-1152.
56. Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1986;1:81-87.
57. Hadlow N, Longhurst K, McClements A, Natalwala J, Brown SJ, Matson PL. Variation in antimullerian hormone concentration during the menstrual cycle may change the clinical classification of the ovarian response. Fertil Steril 2013;99:1791-1797.
58. Hagen CP, Sorensen K, Anderson RA, Juul A. Serum levels of antimullerian hormone in early maturing girls before, during, after suppression with GnRH agonist. Fertil Steril 2012;98:1326-1330.
59. Han X, McShane M, Sahertian R, White C, LedgerW. Pre-mixing serum samples with assay buffer is a prerequisite for reproducible anti-Mullerian hormone measurement using the Beckman Coulter Gen II assay. Hum Reprod 2014;29:1042-1048.
60. Hansen KR, Morris JL, Thyer AC, Soules MR. Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting. Fertil Steril 2003; 80:577-583.
61. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 2011; 95:170-175.
62. Hehenkamp WJ, LoomanCW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006;91:4057-4063.
63. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB, MacLaughlin DT. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 1990;70:16-22.
64. Iglesias C, Banker M, Mahajan N, Herrero L, Meseguer M, Garcia-Velasco JA. Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women. Fertil Steril 2014;102:244-249.
65. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013;98:3332-3340.
66. Iliodromiti S, KelseyTW, WuO, Anderson RA, Nelson SM. The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update 2014;20:560-570.
67. Immunotech AMH (Beckman Coulter) package insert 2012. Available at: https://www.beckmancoulter.com/wsrportal/ajax/./A118932012-06-05_GB.pdf (May 2014, date last accessed).
68. Jayaprakasan K, WalkerKF, Clewes JS, Johnson IR, Raine-Fenning NJ. The interobserver reliability of off-line antral follicle counts made from stored three-dimensional ultrasound data: a comparative study of different measurement techniques. Ultrasound Obstet Gynecol 2007;29:335-341.
69. Jayaprakasan K, Campbell BK, Clewes JS, Johnson IR, Raine-Fenning NJ. Threedimensional ultrasound improves the interobserver reliability of antral follicle counts and facilitates increased clinical work flow. Ultrasound Obstet Gynecol 2008; 31:439-444.
70. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 2010;93:855-864.
71. Jeppesen JV, Anderson RA, KelseyTW, Christiansen SL, Kristensen SG, Jayaprakasan K, Raine-Fenning N, Campbell BK, Yding Andersen C. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod 2013;19:519-527.
72. Josso N, Legeai L, Forest MG, Chaussain JL, Brauner R. An enzyme linked immunoassay for anti-mullerian hormone: a new tool for the evaluation of testicular function in infants and children. J Clin Endocrinol Metab 1990;70:23-27.
73. Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS. Antimullerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril 2013;99:1305-1310.
74. Kelly SM, Sladkevicius P, Campbell S, Nargund G. Investigation of the infertile couple: a one-stop ultrasound-based approach. Hum Reprod 2001;16:2481-2484.
75. KelseyTW, Wright P, Nelson SM, Anderson RA, Wallace WHB. Avalidated model of serum anti-Müllerian hormone from conception to menopause. PLoS One 2011;6: e22024.
76. Kelsey TW, Anderson RA, Wright P, Nelson SM, Wallace WH. Data-driven assessment of the human ovarian reserve. Mol Hum Reprod 2012;18:79-87.
77. Kissell KA, Danaher MR, Schisterman EF, Wactawski-Wende J, Ahrens KA, Schliep K, Perkins NJ, Sjaarda L, Weck J, Mumford SL. Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women. Hum Reprod 2014;29:1764-1772.
78. Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE. Development of a second generationanti-Müllerian hormone (AMH)ELISA. J ImmunolMethods 2010;362:51-59.
79. Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-Mullerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2008;90:737-743.
80. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20:124-140.
81. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006;21:3103-3107.
82. La Marca A, Spada E, Sighinolfi G, Argento C, Tirelli A, Giulini S, Milani S, Volpe A. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. Fertil Steril 2011;95:684-688.
83. La Marca A, Papaleo E, Grisendi V, Argento C, Giulini S, Volpe A. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG 2012; 119:1171-1179.
84. La Marca A, Grisendi V, Giulini S, Argento C, Tirelli A, Dondi G, Papaleo E, Volpe A. Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count. J Ovarian Res 2013;6:11.
85. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A, Hougaard DM, Nyboe Andersen A. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 2014;29:791-801.
86. Lawrenz B, Fehm T, vonWolff M, Soekler M, Huebner S, Henes J, Henes M. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma-evaluation by using antimullerian hormone and retrieved oocytes. Fertil Steril 2012;98:141-144.
87. Leonhardt H, Gull B, Stener-Victorin E, HellstromM. Ovarian volume and antral follicle count assessed by MRI and transvaginal ultrasonography: a methodological study. Acta Radiol 2014a;55:248-256.
88. Leonhardt H, Hellstrom M, Gull B, Lind AK, Nilsson L, Janson PO, Stener-Victorin E. Ovarian morphology assessed by magnetic resonance imaging in women with and without polycystic ovary syndrome and associations with antimullerian hormone, free testosterone, and glucose disposal rate. Fertil Steril 2014b; 101:1747-1756.e3.
89. McIlveen M, Skull JD, Ledger WL. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod 2007;22:778-785.
90. Melo MA, Garrido N, Alvarez C, Bellver J, Meseguer M, Pellicer A, Remohí J. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil Steril 2009;91:148-156.
91. Merce LT, Gomez B, Engels V, Bau S, Bajo JM. Intraobserver and interobserver reproducibility of ovarian volume, antral follicle count, and vascularity indices obtained with transvaginal 3-dimensional ultrasonography, power Doppler angiography, and the virtual organ computer-aided analysis imaging program. J Ultrasound Med 2005;24:1279-1287.
92. MHRA. Urgent field safety notice-FSN 20434-3. AMH Gen II ELISA (REF A79765). Medicines and Healthcare Products Regulatory Agency 2013.
93. MutluMF, Erdem M, Erdem A, Yildiz S, Mutlu I, Arisoy O, OktemM. Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. J Assist Reprod Genet 2013; 30:657-665.
94. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG 2005;112:1384-1390.
95. Nardo LG, Christodoulou D, Gould D, Roberts SA, Fitzgerald CT, Laing I. Anti-Mullerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol 2007;23:486-493.
96. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril 2013;99:963-969.
97. Nelson SM, YatesRW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 2007;22:2414-2421.
98. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867-875.
99. Nelson SM, Stewart F, Fleming R, Freeman DJ. Longitudinal assessment of antimullerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril 2010;93:1356-1358.
100. Nelson SM, Messow MC, McConnachie A, Wallace H, Kelsey T, Fleming R, Anderson RA, Leader B. External validation of nomogram for the decline in serum anti-Mullerian hormone in women: a population study of 15, 834 infertility patients. Reprod Biomed Online 2011a;23:204-206.
101. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimullerian hormone: a population study of 9, 601 infertility patients. Fertil Steril 2011b;95:736-U813.
102. Nelson SM, Telfer EE, Anderson RA. The ageing ovary and uterus: new biological insights. Hum Reprod Update 2013;19:67-83.
103. Nelson SM, Iliodromiti S, Fleming R, Anderson R, McConnachie A, Messow CM. Reference range for the antimullerian hormone Generation II assay: a population study of 10, 984 women, with comparison to the established Diagnostics Systems Laboratory nomogram. Fertil Steril 2014;101:523-529.
104. Oehinger S, Nelson SM, Verwij P, Stegmann B. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation. Hum Reprod 2013;28(suppl 1):i311-i356.
105. Overbeek A, Broekmans FJ, Hehenkamp WJ, Wijdeveld ME, van Disseldorp J, van Dulmen-den Broeder E, Lambalk CB. Intra-cycle fluctuations of anti-Mullerian hormone in normal women with a regular cycle: a re-analysis. Reprod Biomed Online 2012;24:664-669.
106. Peters H, Byskov AG, Grinsted J. Follicular growth in fetal and prepubertal ovaries of humans and other primates. Clin Endocrinol Metab 1978;7:469-485.
107. Randolph JF Jr., Harlow SD, Helmuth ME, Zheng H, McConnell DS. Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle. Hum Reprod 2014; 29:592-600.
108. Şenateş E, Çolak Y, Erdem ED, Yeşil A, Coşkunpinar E, ŞahinÖ, Altunöz ME, Tuncer I, Kurdaş Ö vünç AO. Serum anti-Müllerian hormone levels are lower in reproductiveage women with Crohn's disease compared to healthy control women. J Crohns Colitis 2013;7:e29-e34.
109. Soto N, Iniguez G, Lopez P, Larenas G, Mujica V, Rey RA, Codner E. Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Hum Reprod 2009;24: 2838-2844.
110. SowersMR, EyvazzadehAD, McConnellD, Yosef M, JannauschML, ZhangD, HarlowS, Randolph JF Jr. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008;93:3478-3483.
111. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 2008;90:395-400.
112. Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Res Treat 2013a; 137:571-577.
113. Su HI, Maas K, Sluss PM, Chang RJ, Hall JE, Joffe H. The impact of depotGnRHagonist on AMH levels in healthy reproductive-aged women. J Clin Endocrinol Metab 2013b; 98:E1961-6.
114. Su HI, Sammel MD, Homer MV, Bui K, Haunschild C, Stanczyk FZ. Comparability of antimullerian hormone levels among commercially available immunoassays. Fertil Steril 2014;101:1766-72 e1.
115. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009;24:1976-1981.
116. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 2007;22:1837-1840.
117. Tunstall-Pedoe H. Cardiovascular Risk and Risk Scores: ASSIGN, Framingham, QRISK and others: how to choose. Heart 2011;97:442-444.
118. Tuttle AM, Stampfli M, Foster WG. Cigarette smoke causes follicle loss in mice ovaries at concentrations representative of human exposure. Hum Reprod 2009; 24:1452-1459.
119. van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC, Broekmans FJ. Comparison of inter-and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 2010;25:221-227.
120. van DorpW, van den Heuvel-Eibrink MM, de Vries AC, Pluijm SM, Visser JA, Pieters R, Laven JS. Decreased serum anti-Mullerian hormone levels in girls with newly diagnosed cancer. Hum Reprod 2014;29:337-342.
121. Van Rooij IAJ, Broekmans FJM, Te Velde ER, Fauser BCJM, Bancsi LFJMM, De Jong FH, Themmen APN. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065-3071.
122. Vosnakis C, Georgopoulos NA, Armeni AK, Papadakis E, Roupas ND, Katsikis I, Panidis D. Sibutramine administration decreases serum anti-Mullerian hormone (AMH) levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2012;163:185-189.
123. WallaceWH, KelseyTW. Human ovarian reserve from conception to the menopause. PLoS One 2010;5:e8772.
124. Wallace AM, Faye SA, Fleming R, Nelson SM. A multicentre evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II). Ann Clin Biochem 2011;48:370-373.
125. Weinberg CR. Toward a clearer definition of confounding. Am J Epidemiol 1993; 137:1-8.
126. Wellons MF, Bates GW, Schreiner PJ, Siscovick DS, Sternfeld B, Lewis CE. Antral follicle count predicts naturalmenopause in a population-based sample: theCoronaryArtery Risk Development in Young AdultsWomen's Study. Menopause 2013;20:825-830.
127. Welsh P, Smith K, Nelson SM. A single-centre evaluation of two new anti-Mullerian hormone assays and comparison with the current clinical standard assay. Hum Reprod 2014;29:1035-1041.
128. Wiweko B, Prawesti DM, Hestiantoro A, Sumapraja K, Natadisastra M, Baziad A. Chronological age vs biological age: an age-related normogram for antral follicle count, FSH and anti-Mullerian hormone. J Assist Reprod Genet 2013;30:1563-1567.
129. Yang YS, Hur MH, Kim SY, Young K. Correlation between sonographic and endocrine markers of ovarian aging as predictors for late menopausal transition. Menopause 2011;18:138-145.
130. Zuccotti M, Merico V, Cecconi S, Redi CA, Garagna S. What does it take to make a developmentally competentmammalian egg? HumReprodUpdate 2011;17:525-540.
131. Zuvela E, Walls M, Matson P. Within-laboratory and between-laboratory variability in the measurement of anti-mullerian hormone determined within an external quality assurance scheme. Reprod Biol 2013;13:255-257.